SCHEMBL5457507

SCHEMBL5457507

NC(=O)c1c(NC(=O)C2CCCO2)sc2c1CCCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 1.00
HPGD P15428 5/20 1.00
MDM2 Q00987 1/20 1.00
KDM4E B2RXH2 5/20 0.98
MAPT P10636 5/20 0.98
RAB9A P51151 2/20 0.98
SMN1; SMN2 Q16637 2/20 0.98
TSHR P16473 3/20 0.95
HSD17B10 Q99714 2/20 0.95
MAPK10 P53779 1/20 0.95
FLT3 P36888 3/20 0.70
HTT P42858 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69
LMNA P02545 3/20 0.65
L3MBTL1 Q9Y468 3/20 0.64
NPC1 O15118 2/20 0.64
MEN1 O00255 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2C19 P33261 1/20 0.60
KMT2A Q03164 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18177320 0.99 ALDH1A1 (1.00) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL5448366 0.85 ALDH1A1 (0.76) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL3922474 0.83 FLT3 (1.00) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL8288845 0.82 FLT3 (0.97) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL3128067 0.82 FLT3 (0.92) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL5455726 0.82 FLT3 (0.97) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL3914689 0.82 FLT3 (0.92) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL3126680 0.81 FLT3 (0.90) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL8288684 0.81 FLT3 (0.90) ALDH1A1HPGDMDM2KDM4EMAPT
SCHEMBL8290415 0.81 FLT3 (0.90) ALDH1A1HPGDMDM2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 ALDH1A1 1153/4885HPGD 2361/4885MDM2 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.